Open API for Global Clinical Trial Data Launched by myTomorrows

Thursday, September 15, 2016 Clinical Trials News J E 4

AMSTERDAM, September 14, 2016 /PRNewswire/ --

myTomorrows, global online facilitator of early access to investigational drugs, has introduced an openly accessible API to open up its comprehensive database of uniform information relating to clinical trials. Data on over 300.000 clinical trials, already accessible via its patient and physician centric website, can now be used by other organisations in their own environments.

"Opening the myTomorrows database is a big push forward to make comprehensive and uniform information on clinical trials freely accessible to anybody who needs it. We hope to see further applications grow out of our data to better serve unmet medical needs globally and advance drug development" COO Robert Kraal explains, setting out myTomorrows' hopes for the development.

The interface can be used to search, filter, and download complete historic clinical trial records data accumulated from all the registries of the World Health Organization's Primary Registry Network of medical trial registration partners. Potential applications include anything from ad-hoc queries by data scientists to patient trial screening to mobile health.

"We have built the API with the intention of making it accessible for the largest group of stakeholders. Using a very simple approach, any programmer can directly access the data in a friendly human-readable format and structure" says Sander Nagtegaal, Chief Technical Officer at myTomorrows.

For technical details, please visit the official documentation, the API terms of service or reach out to directly.

SOURCE myTomorrows



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Costa Rica Will Host the Largest Latin American Fo...
Novartis survey published in The Breast Journal re...